High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not

Human Pathology

Volumn 42, Issue 6, 2011, Pages 867-872

  Findeis Hosey, Jennifer J ^a   Huang, Jiaoti ^b   Li, Faqian ^a   Yang, Qi ^a   McMahon, Loralee A ^a   Xu, Haodong ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atypical carcinoid; Large cell neuroendocrine carcinoma; EZH2; Lung; Neuroendocrine tumors; Small cell lung carcinoma; Typical carcinoid

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR EZH2;

ARTICLE; CANCER TISSUE; CARCINOID; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MEDIASTINUM LYMPH NODE; NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; TISSUE SECTION;

CARCINOID TUMOR; CARCINOMA, NEUROENDOCRINE; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 79956132811     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.09.019     Document Type: Article

References (25)

1. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon (France): IARC Press; 2004.
2. Zeidler M, Kleer CG. The polycomb group protein enhancer of zeste 2: its links to DNA repair and breast cancer. J Mol Histol 2006;37:219-23. (Pubitemid 44795625)
3. Barski A, Cuddapah S, Cui K, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007;129:823-37. (Pubitemid 46802390)
4. Watanabe H, Soejima K, Yasuda H, et al. Deregulation of histone lysine methyltransferases contributes to oncogenic transformation of human bronchoepithelial cells. Cancer Cell Int 2008;8:15.
5. Simon JA, Tamkun JW. Programming off and on states in chromatin: mechanisms of polycomb and trithorax group complexes. Curr Opin Genet Dev 2002;12:210-8. (Pubitemid 34219494)
6. Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268-73. (Pubitemid 46622055)
7. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
8. Kleer CG, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11. (Pubitemid 37205983)
9. Raaphorst FM, Meijer CJ, Fieret E, et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003;5:481-8. (Pubitemid 38045085)
10. Sudo T, Utsunomiya T, Mimori K, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005;92:1754-8. (Pubitemid 40756488)
11. Arisan S, Buyuktuncer ED, Palavan-Unsal N, et al. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 2005;75:252-7. (Pubitemid 41433876)
12. Poulsen TT, Pedersen N, Juel H, Poulsen HS. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Cancer Gene Ther 2008;15:563-75.
13. Matsukawa Y, Semba S, Kato H, et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006;97:484-91. (Pubitemid 43811589)
14. Hinz S, Weikert S, Magheli A, et al. Expression profile of the polycomb group protein enhancer of zeste homologue 2 and its prognostic relevance in renal cell carcinoma. J Urol 2009;182:2920-5.
15. Cai GH, Wang K, Miao Q, Peng YS, Chen XY. Expression of polycomb protein EZH2 in multi-stage tissues of gastric carcinogenesis. J Dig Dis 2010;11:88-93.
16. Raaphorst FM, van Kemenade FJ, Blokzijl T, et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000;157:709-15. (Pubitemid 32109362)
17. Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J 2003;22:5323-35. (Pubitemid 37279943)
18. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 2003;95:661-8. (Pubitemid 36603722)
19. Raman JD, Mongan NP, Tickoo SK, et al. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005;11:8570-6. (Pubitemid 43005902)
20. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006;12:1168-74. (Pubitemid 43342505)
21. Ding L, Kleer CG. Enhancer of zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 2006;66:9352-5. (Pubitemid 44623628)
22. Xu H, Bourne PA, Spaulding BO, Wang HL. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. HUM PATHOL 2007;38:555-63. (Pubitemid 46399894)
23. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science 2002;298:1039-43. (Pubitemid 35247314)
24. Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008;322:1695-9.
25. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98. (Pubitemid 43357945)